Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Oxycodone combined with pulsed radiofrequency for refractory cancer pain from spinal metastases: a randomized controlled study.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the clinical efficacy and safety of oxycodone combined with pulsed radiofrequency (PRF) in the treatment of refractory cancer pain (RCP) arising from spinal metastasis.
methodsA randomized controlled trial enrolled 60 patients with RCP due to spinal metastases. Participants were randomly allocated to the oxycodone alone group (Group A, n = 30) or the oxycodone combined with PRF group (Group B, n = 30). Primary outcomes comprised pain scores on the Numerical Rating Scale (NRS) and episodes of breakthrough pain at post-treatment time points Secondary endpoints included opioid consumption, immune parameters, quality of life, and adverse event incidence.
resultsGroup B had significantly lower NRS scores and fewer 24-h breakthrough pain episodes than Group A at post-treatment time points (p < 0.05). The opioid consumption and 7/30-day drug escalation indices of Group B were significantly lower (p < 0.05), with a lower dose escalation rate (46.67% vs. 73.33%, p = 0.035). Group B exhibited relatively better preserved selected T lymphocyte subset parameters (CD3⁺, CD4⁺ T cell percentages, CD4⁺/CD8⁺ ratio) and quality of life scores (p < 0.05), with a markedly lower overall adverse reaction rate (43.33% vs. 70.00%, p = 0.037) and no serious adverse events observed.
conclusionsThis exploratory pilot randomized controlled trial indicated that the combination of oxycodone and PRF may contribute to improved pain control, decreased opioid consumption, and attenuated decline in lymphocyte subsets alongside enhanced quality of life in patients with spinal metastasis-related refractory cancer pain. No serious adverse events were documented. The clinical and oncological significance of the observed intergroup differences in T cell indices remains unclear. These preliminary observations require verification in larger prospective trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.